Fig. 7: Combination treatment with α-PD-1 and PARP14 inhibition induces an inflammatory response. | Nature Communications

Fig. 7: Combination treatment with α-PD-1 and PARP14 inhibition induces an inflammatory response.

From: PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models

Fig. 7: Combination treatment with α-PD-1 and PARP14 inhibition induces an inflammatory response.The alternative text for this image may have been generated using AI.

A GSEA based on RNA-seq data depicting hallmark processes enriched in chronic IFNγ pre-treated tumours treated with α-PD-1 alone (n = 4) versus Control (n = 4); combined αPD-1 and PARP14 inhibition (Combo) (n = 4) versus α-PD-1 alone (n = 4); Combo (n = 4) versus Control (n = 4). Circle area depicts the NES, and colour intensity depicts the FDR, with ≤0.25 classed as significant. B–C Ingenuity Pathway Analysis (IPA) was performed to identify up- or down-regulation of B upstream regulators and C disease-related or functional pathways in tumours receiving α-PD-1/PARP14i combination treatment (n = 4) versus α-PD-1 alone treatment (n = 4). Results were displayed with their P-value (-log(P-value)) and activation z-score. The p-values were assessed by two-tailed unpaired t-test. D–L Bulk-tumour RNA-seq results treated with Control (n = 4); PD-1 + Vehicle (n = 4); or PD-1 + PARP14i (n = 4) analysed by cell-type enrichment analysis (ImmuCellAI), with scores shown for D infiltration, E T cell, F M1 macrophage, G CD8 central memory (CM) T cells, H CD8 effector memory (EM) T cells, I exhausted (Ex) CD8 T cells, J Granulocytes, K Myeloid Dendritic cell (MoDC), L CD8 cytotoxic T cell (Tc). The data were presented as mean ± S.E.M. and the adjusted p-values were determined by one-way ANOVA Tukey’s test. Source data are provided as a Source Data file.

Back to article page